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Abstract 
The left atrial appendage (LAA) is an area of interest because of its thrombogenic 
potential in patients with atrial fibrillation. The current standard for LAA removal is 
epicardial excision, which may leave residual volume thereby undermining its effectiveness. 
Also, LAA surgery may injure the nearby circumflex artery. This investigation aims to 
measure the proximity of the circumflex artery to the LAA at various points, and evaluate 
pericardial patch exclusion as a novel method of LAA closure in a cadaveric model. After 
performing both procedures in all (n=27) hearts, epicardial excision left 24% of the original 
volume while pericardial patch exclusion left 4%. The circumflex artery was closest to the 
LAA at the 4 o’clock position. These results suggest that physicians should beware of the 
injuring the circumflex artery at 4 o’clock and that pericardial patch exclusion may be a 
viable alternative for surgical LAA closure in patients with atrial fibrillation. 
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Chapter 1  
1 Introduction and Literature Review 
1.1 Introduction 
The left atrial appendage (LAA), also called the auricle, is a remnant of the 
embryological development of the heart. It is an out-pocketing of the wall of the left 
atrium and has an orifice through which blood can enter and exit1. The LAA has some 
physiological function, but its anatomy is most problematic for patients with atrial 
fibrillation (AF). Patients with AF have a dramatically increased risk of stroke due to 
blood clots that form as a result of their abnormal and irregular heartbeat2. These patients 
are prescribed oral anticoagulants, namely warfarin, to help reduce this risk, but many of 
them cannot take warfarin long term3. The majority of blood clots in patients with AF 
form within the LAA, due to the stagnation and pooling of blood that occurs therein, so 
surgical resection of the appendage is an option for stroke risk reduction4. Surgical 
closure of the LAA can be done by exclusion or by excision. Exclusion involves suturing 
or stapling the orifice of the LAA closed so that blood no longer enters, effectively 
eliminating the appendage. Excision involves cutting the appendage off and suturing the 
remnant shut. Excision is the option most surgeons prefer, but it is difficult to achieve 
complete resection of the LAA5. A residual LAA stump, one that blood can still enter, 
has been shown to be possibly even more dangerous than an intact LAA6. Dr. Michael 
W.A. Chu, a cardiac surgeon at London Health Sciences Centre (LHSC), has developed 
an unpublished novel technique for LAA closure called pericardial patch exclusion that 
involves suturing a patch of the patient’s pericardium over the LAA orifice. Any surgery 
on the LAA, whether performed endocardially or epicardially, runs the risk of damaging 
the circumflex coronary artery that runs in close proximity to the base of the appendage7. 
1.2 The Heart 
1.2.1 Anatomy and Function 
The heart is a muscular organ that pumps blood through the circulatory system, 
providing tissues with oxygen and nutrients and removing metabolic waste products8. It 
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is located in the middle mediastinum of the thorax, sitting on the central tendon of the 
diaphragm9. It is situated between the right and left lungs, posterior to the sternum and 
costal cartilages and anterior to the oesophagus, descending aorta and thoracic vertebrae. 
In normal adults, the heart is roughly the size of a fist and weighs approximately 300 
grams9.  
It is enclosed in the pericardium, a double-membrane sac that provides protection 
to the heart, lubricates its rotational movement, and prevents it from overfilling8. The 
outer layer is the tough fibrous pericardium, which blends with the central tendon of the 
diaphragm and the walls of the great vessels leaving the heart. The inner layer, the serous 
pericardium, is itself made up of two layers. The parietal layer lines the inside of the 
fibrous pericardium, and the visceral layer sits immediately on top of the heart as the 
epicardium. These two layers of are continuous with one another at the roots of vessels 
entering and leaving the heart9. The serous pericardium secretes a small amount of 
pericardial fluid into the space between its two layers – the pericardial space – that acts to 
reduce friction as the heart moves during its normal rhythm8.  
The heart is made of four chambers, two atria located more superiorly and two 
ventricles inferior to them. The atria are relatively featureless chambers, in comparison to 
the ventricles, which receive blood from the body and the lungs and pump it to the 
ventricles. Their walls are thinner and mostly smooth, but also exhibit some comb-like 
muscular ridges called pectinate muscles9. Each atrium is separated from the ventricle by 
atrioventricular (AV) valves. The right AV valve has three cusps, while the left AV valve 
– the mitral valve – has two. The ventricles are separated from the great vessels leaving 
the heart by semilunar valves, a pulmonary valve on the right side and an aortic valve on 
the left side. Relative to the atria, the ventricles have much thicker walls, the interiors of 
which are covered in columns of muscle called trabeculae carnae9. The ventricles also 
contain papillary muscles, which connect to chordae tendineae, thin string-like tendons 
that attach to the cusps of the AV valves. During contraction of the ventricles, the 
papillary muscles contract and pull on the chordae tendineae, keeping the AV valve shut 
against intraventricular pressure and preventing backflow of blood into the atria8.  
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The right atrium receives deoxygenated blood from the body via the superior and 
inferior vena cava and sends it to the right ventricle through the right (tricuspid) AV 
valve. The right ventricle pumps blood through the pulmonary semilunar valve to the 
pulmonary trunk, which divides into the left and right pulmonary arteries taking blood to 
the lungs8. Once the blood is oxygenated it returns to the left atrium of the heart via four 
pulmonary veins, two from each lung. Blood then passes through the mitral valve to the 
left ventricle, from which it is pumped through the aortic semilunar valve into the aorta, 
taking it to the rest of the body8. 
1.2.2 The Left Atrial Appendage 
 The walls of both of the atria have a small out-pocketing that is the result of the 
embryological development of the heart. These out-pocketings are called the auricles or 
the atrial appendages1. The left atrial appendage (LAA) is a long, tubular structure with 
an opening, called the LAA orifice, which opens into the left atrial cavity1 (Figure 1.2.2). 
It is smaller than the right atrial appendage, and can have many lobes and bends10. During 
the embryological development of the heart, the pulmonary veins grow to form most of 
the wall of the left atrium and what began as the left atrial cavity forms the LAA. For this 
reason, the interior wall of the LAA contains an abundance of pectinate muscle, which is 
mostly absent from the rest of the left atrium1.  
Ernst and colleagues (1995), using resin casts of 
post-mortem LAAs, have noted great variability in the 
shape and size of the LAA, as well as its number of lobes 
and branches11. Lacomis and colleagues (2007) used CT 
images to visualize the LAA and found broad variation 
between individuals in terms of LAA morphology, 
dimensions, angulation and motility12. In live patients the 
LAA is typically visualized using transesophageal 
echocardiogram (TEE) or CT scan. However, because of 
the wide variation in the morphology of the LAA, 
especially in its number of lobes and complex branching 
patterns, it is difficult to accurately image the LAA using these methods11,13. A few 
Figure 1.2.2 The left 
atrial appendage (LAA). 
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studies have attempted to describe the variability in LAA morphology by dividing them 
into categories. Di Biase and colleagues (2012) used MRI and CT imaging to describe 
932 LAAs and assign them to one of four categories based on their shape: cactus, chicken 
wing, windsock and cauliflower14. The cactus LAA has a dominant central lobe with 
secondary lobes extending superiorly and inferiorly. The chicken wing LAA has an 
obvious bend in the middle portion and may fold back towards the heart. The windsock 
LAA has a single dominant lobe as its primary structure. Finally, the cauliflower LAA is 
relatively short with a complex internal structure14. Conversely, in the same year Shi and 
colleagues (2012) used angiography to image the LAA in 75 Chinese patients and 
divided them into eight categories, also based on their shape: tube, claw, sphere-like, 
tadpole, willow-leaf, sword, duckbill and irregular15. Besides the appendage itself, the 
LAA orifice has also been categorized based on shape. Wang and colleagues (2010) used 
CT to image 612 hearts and described five categories of the orifice. The majority were 
oval (69%), and the remainder were foot-like, triangular, water drop-like and round16. 
Studies like these serve to illustrate just how much one LAA differs from the next. 
Despite this wide variation, there have been studies that have attempted to 
measure and describe the average dimensions of the left atrial appendage. In 1995, Ernst 
and colleagues measured casts of 220 post-mortem hearts and found the following mean 
LAA measurements: length of 30 mm, width of 31 mm, volume of 5.2 mL, orifice major 
axis of 21 mm and orifice minor axis of 15 mm11. In 1996, Rubin and colleagues used 
TEE to evaluate the LAA in 100 patients and found a mean length of 51 mm and a mean 
width of 47 mm17. In 2003, Stollberger and colleagues attempted to compare TEE to 
post-mortem casts of the LAA in order to assess the accuracy of TEE. By TEE they 
found a mean length of 47.5 mm, width of 36.5 mm, orifice major axis of 23.3 mm and 
orifice minor axis of 16.8 mm. By cast they found a mean length of 30.8 mm, orifice 
major axis of 21.6 mm, orifice minor axis of 17.0 mm and volume of 7.0 mL13. In 2007, 
Lacomis and colleagues used CT imaging of 25 hearts to find a mean LAA length of 52.2 
mm12. Also in 2007, Su and colleagues made casts of 31 LAAs and found a mean length 
of 44.9 mm, orifice major axis of 17.4 mm and orifice minor axis of 10.9 mm7. Finally in 
2012, after performing angiography to image the hearts of 75 patients, Shi and colleagues 
found a mean LAA length of 35.6 mm, LAA width of 18.5 mm and orifice major axis of 
5 
 
17.3 mm15. Veinot and colleagues studied 500 autopsied hearts in order to look at age 
related changes in the LAA. The study revealed that with age, the LAA orifice gets larger 
and the appendage increases in width, while its length remains relatively constant. Age 
and sex were the primary determinants of LAA dimensions, more so than patient height, 
weight and body surface area18. 
While some believe that the LAA has minimal useful function19, it does play 
some physiological role. Tabata and colleagues (1998) have described the role of the 
LAA as a reservoir in the presence of pressure or volume overload, due to its increased 
dispensability compared to the rest of the left atrium20. The LAA has also been described 
as an important source of atrial natriuretic peptide (ANP), which is released in response 
to increased blood volume and stimulates excretion of water, sodium and potassium. 
Bilateral atrial appendectomy in dogs has been found to eliminate the release of ANP and 
blunt renal excretion of sodium and water21. Rodeheffer and colleagues (1993) measured 
ANP levels in fresh tissue from human hearts and found that ANP concentration in the 
right and left atrial appendages was 40-fold higher than in the rest of the heart22. Cardiac 
surgeries that involve removal of the appendages attenuate ANP secretion post-
operatively23. In addition to ANP, the LAA is also a source of brain natriuretic 
polypeptide (BNP)24. 
1.2.3 Coronary Circulation 
 The heart is a muscle that requires oxygen and nutrients to function properly. 
Coronary circulation refers to the network of blood vessels that delivers blood to the 
myocardium, the muscle of the heart. Coronary arteries take oxygenated and nutrient-rich 
blood to the myocardium and coronary veins take deoxygenated and nutrient-poor blood 
away from the myocardium. These coronary vessels run just deep to the epicardium on 
the surface of the heart8.  
The two main coronary arteries, right and left, originate from the very first part of 
the ascending aorta with their openings lying in the cusps of the aortic semilunar valves. 
As the heart relaxes just after the ventricles contract, blood fills the two main coronary 
arteries and the heart muscle is perfused8. The right coronary artery (RCA) originates 
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from the right aortic sinus and runs in the right coronary sulcus, which separates the right 
atrium from the right ventricle. The RCA gives off a small branch to the SA node near its 
origin, and later gives off a right marginal branch that runs down the right border of the 
heart towards the apex. It continues its course to the posterior of the heart in the coronary 
sulcus, and gives off another small branch to the AV node. In most hearts, the RCA 
terminates as the posterior interventricular artery, which runs in the posterior 
interventricular sulcus towards the apex of the heart8. The left coronary artery (LCA) 
originates from the left aortic sinus and emerges from behind the pulmonary trunk, 
running between it and the left atrial appendage, and divides into two major branches. 
The first branch is the anterior interventricular artery, also called the left anterior 
descending (LAD) artery. This artery runs towards the apex of the heart in the anterior 
interventricular sulcus. The second branch is the circumflex artery, which turns to the left 
and follows the left coronary sulcus towards the posterior of the heart, curving around the 
LAA. It gives off the left marginal artery, which runs down the left border of the heart 
towards the apex8. 
Coronary dominance refers to an individual heart’s pattern of coronary arteries, 
and specifically to whether the posterior interventricular artery arises from the RCA or 
the LCA. A heart is right dominant if the posterior interventricular artery arises from the 
RCA, left dominant if it arises from the circumflex artery of the LCA, and co-dominant if 
it receives contributions from both the RCA and LCA25. A study of 110 Brazilian hearts 
found that 69% were right dominant, 12% were left dominant, and 19% were co-
dominant26. Another study, this one of the population of Assam, India, found that 70% 
were right dominant, 19% were left dominant, and 11% were co-dominant27. According 
to these studies and others, the majority of individuals have right dominant coronary 
circulation. The network of coronary veins more or less accompanies the arteries and 
drains the myocardium of deoxygenated blood, returning it to the right atrium via the 
coronary sinus and the anterior cardiac veins8.  
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1.3 Atrial Fibrillation 
1.3.1 Introduction 
 Atrial fibrillation (AF) is a condition that involves irregular or abnormal beating 
of the heart, known as arrhythmia. It is the most common form of arrhythmia, affecting 
approximately 350,000 Canadians28, and 2-3% of the population of Europe29. AF is 
characterized by a rapid and irregular heartbeat and fluttering of the two atria25. The risk 
of developing it greatly increases with age, as well as with coincidence of high blood 
pressure, heart valve diseases, other underlying heart problems, and excessive alcohol 
consumption30. In a longitudinal study of 5,201 patients over the age of 65, AF was 
diagnosed in 4.8% of women and 6.2% of men31. Lernfelt and colleagues (2014) looked 
at the incidence of AF in 2,629 elderly patients. They found that at 70 years of age 5.2% 
of men and 2.2% of women had AF, at 80 years 13.7% of men and 7.5 of women did, at 
90 years 20.4% of men and 17.3% of women did, and at 100 years 33% of men and 
26.8% of women had AF75. Patients with AF can experience chest pain, shortness of 
breath, fatigue, dizziness and light-headedness. However, the main concern in these 
patients is a greatly increased risk of stroke due to turbulent blood flow and stasis of 
blood in the heart25. Patients with AF have a fivefold increased risk of stroke over the 
general population2. These patients experience approximately 17% of all ischemic 
stroke32, and roughly 35% of them will have a stroke during their lifetime4. 
1.3.2 Pathogenesis 
 The beating of the heart is stimulated and controlled by the electrical conduction 
system of the heart. Electrical impulses spread throughout the muscle of the heart, 
exciting them and causing them to contract8. The impulse for a heartbeat originates in the 
sinoatrial (SA) node, also known as the pacemaker of the heart, located in the wall of the 
right atrium. From there, the signal spreads throughout the atria, stimulating them to 
contract. It reaches the atrioventricular (AV) node, which is located at the junction of the 
four heart chambers, where the signal is delayed for a fraction of a second to allow the 
ventricles to fill with blood. The signal is then sent down through the bundle of His and 
the bundle branches towards the apex of the heart. From the apex, the signal reaches the 
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myocardial cells via Purkinje fibres, stimulating contraction. This arrangement ensures 
that the ventricles contract from the bottom up, allowing efficient emptying of blood to 
the great vessels33. 
 The normal functioning of the electrical conduction system of the heart ensures 
synchronized contraction of the myocardium, which is important for a couple of reasons. 
First, it causes smooth laminar flow of blood through the heart. Second, it results in 
complete filling and emptying of the hearts chambers, which helps keep blood moving 
and prevents pooling and stasis33. In patients with atrial fibrillation, normal impulses 
from the SA node are overpowered by disorganized electrical impulses from elsewhere in 
the atria, most commonly from the roots of the left pulmonary veins33. This causes the 
atria to beat rapidly, incompletely and irregularly. This fluttering of the atria causes 
turbulent blood flow through the heart, and since the atria do not empty completely, 
blood pools. Both of these factors lead to increased thrombogenesis, or blood clot 
formation in the atria. This is very dangerous because a blood clot in the left atrium can 
break off and embolize, and may travel to the brain and occlude one of those blood 
vessels, causing a stroke33. 
1.3.3 Treatment 
 There are many strategies for the treatment of atrial fibrillation, but they generally 
fall under a few categories. The first step is to return the patient’s heart to normal sinus 
rhythm. This is called “rhythm control” and it can be done in two ways. The first is with 
medication; there are several drugs that can help re-establish sinus rhythm. The second is 
via electrical cardioversion, which involves delivering an electrical shock to the heart 
while the patient is under sedation. This temporarily stops the conduction system of the 
heart, and the hope is that when it restarts it is driven by the SA node again28,33,34. The 
second step in AF treatment is “rate control”. This entails decreasing the heart rate, since 
it is frequently elevated in AF due to the increased frequency of impulses to the AV node 
stimulating the ventricles. Medications used for this purpose include beta-blockers, 
calcium channel blockers and digoxin28,33,34. If these strategies do not work, more 
permanent treatments are available. One of these treatments is catheter ablation, wherein 
a catheter is inserted into the femoral vein in the groin and threaded up to the heart. Once 
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in the atria, the catheter is used to deliver radiofrequency energy to ‘hot spots’ in the 
heart wall, which are parts of the wall that are generating the impulses that overpower the 
SA node. The radiofrequency energy ablates or scars the problem tissue, rendering it 
unable to evoke an electrical signal and allowing the SA node to generate its normal 
impulses28,33,34. If all else fails, there is a surgical treatment for atrial fibrillation called the 
MAZE procedure, developed by Dr. James Cox and colleagues in 1987. The MAZE 
procedure involves making patterned incisions in the atrial walls, as well as removal of 
the atrial appendages. The resulting patterns of scar tissue block abnormal signal circuits 
and prevent the spread of disorganized signals, allowing the SA node to take over and 
restoring sinus rhythm28,33,34,35. 
 Because the biggest concern and most serious potential complication for patients 
with atrial fibrillation is the formation of blood clots and embolization to the brain, most 
AF patients are prescribed blood thinners, or anticoagulants, to prevent 
thrombogenesis28,33,34. Warfarin, brand name Coumadin, is used in most cases and is the 
gold standard. One study found that warfarin consistently decreases the risk of stroke in 
AF patients by 68%36. Another meta-analysis of studies looking at stroke risk reduction 
in AF patients found that therapy with adjusted-dose warfarin reduces the relative risk of 
stroke by 62%37. 
1.3.4 Significance of the Left Atrial Appendage 
 The LAA has been recognized as a major site of origin for thrombi in patients 
with AF. In 1969, Aberg reviewed 642 patients with AF and found that 43 thrombi and 
29 systemic emboli originated in the LAA vs. 22 thrombi and 16 systemic emboli from 
the rest of the left atrium38. Stoddard and colleagues (1995) performed TEE in 317 AF 
patients and found thrombi in the LAA of 21% of them39. In 1995, Manning and 
colleagues performed TEE in 233 patients with AF who were not on long-term 
anticoagulation, and found that after a period of 48 hours of atrial fibrillation, 15% of 
these patients had left atrial thrombus and all but one of those were in the LAA40. In 
1996, Blackshear and Odell published possibly the most cited paper regarding the 
prevalence of thrombi in the LAA. They performed a meta-analysis of previous studies 
and found that in patients with rheumatic AF, 57% of thrombi originated in the LAA, and 
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in patients with non-rheumatic AF, 91% of thrombi originated therein4. From these 
studies it is clear that in patients with atrial fibrillation, blood clots form in the LAA more 
often than anywhere else in the heart. It has been found that LAA function and 
morphology may play a role in increasing the risk of thrombogenesis. The poor pumping 
function of the LAA41 and its complex shape42 lead to stasis of blood within the 
appendage, which leads to clotting. The right atrial appendage may be a site of 
thrombogenesis as well, however it is less likely and less of a concern. The right atrial 
appendage is generally more broad and shorter than its counterpart on the left atrium, so 
blood does not pool as much, making it a less conducive environment for blood clot 
formation. Also it is important to note that a thromboembolism from the right atrium 
would lead to pulmonary embolism, while one from the left atrium leads to stroke. While 
pulmonary embolism is still a serious condition, it is not nearly as devastating as a stroke, 
so thrombogenesis in the right atrial appendage is less of a concern than in the LAA. 
1.4 Surgical LAA Obliteration 
1.4.1 Introduction 
 While oral anticoagulation with warfarin is the gold standard treatment for atrial 
fibrillation, it is not always used. One meta-analysis posited that warfarin might not be 
effective for long-term use because anticoagulation therapy is difficult to sustain in 
elderly patients due to increased risk of bleeding and the drug’s narrow therapeutic 
window37. A review article in 2000 stated that warfarin was underused and put forward 
several reasons as to why this is the case. It found that a patient’s age, perceived lack of 
embolic risk, and haemorrhage risk all influence a physician’s decision to not prescribe 
warfarin. Many physicians also consider it impractical and inconvenient to monitor a 
patient’s warfarin levels as necessary3. Cohen and colleagues (2000) found that warfarin 
use falls short of recommendations and cited old age, language difficulties, patient 
disability, and insufficient awareness of its benefits as causes for the reluctance of 
physicians to treat patients with warfarin43. An important reason for the underuse of 
warfarin is the risk of complications. Patients with increased age (65+ years), diabetes 
mellitus, and those who take more than three drugs per day are at an increased risk of 
complications from warfarin use44. It is important to note that it is these older patients 
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who are most likely to develop atrial fibrillation and require treatment with warfarin in 
the first place. In one study, of all AF patients who were at moderate to high risk of 
stroke and were not a high bleeding risk, only 53% received warfarin therapy. Further, 
among patients who did receive warfarin, only 40% were adherent45. So even though it is 
effective at reducing stroke risk in patients with AF, for several reasons warfarin cannot 
be used in many cases. 
 Because the majority of thrombi occurring in patients with atrial fibrillation 
originate in the LAA, surgical closure of the appendage is a viable alternative when 
warfarin cannot be administered4. Johnson and colleagues (2000) evaluated prophylactic 
removal of the LAA for any patient undergoing open-heart surgery in order to reduce 
stroke risk due to potential future development of atrial fibrillation. They found it safe 
and effective and recommended the procedure19. In fact, closure of the LAA has been 
found to be non-inferior to warfarin for prevention of stroke in patients with AF46. 
Closure of the LAA is often done concomitantly with other cardiac surgeries. It is 
relatively easy and safe, and has minor risks and huge potential benefits. Surgical LAA 
obliteration is recommended in the American College of Cardiology/American Heart 
Association Guidelines for patients undergoing mitral valve surgery47, and many studies 
have been carried out evaluating LAA closure during operations involving the mitral 
valve6,48,49. The MAZE procedure for treatment of atrial fibrillation involves resection of 
the atrial appendages35. Sueda and colleagues developed a procedure for left atrial 
ablation in patients with chronic AF associated with mitral valve disease, which also 
involves excision of the LAA50. Finally, LAA closure has also been performed in 
conjunction with coronary artery bypass grafting51. LAA closure can be done surgically, 
via exclusion or excision, or percutaneously with an occluding device. 
1.4.2 Percutaneous Occlusion Devices 
 In recent years, devices to occlude the LAA that are introduced percutaneously 
have been developed. A catheter is used to deliver the device into the venous system and 
threaded up to the right atrium. From there the atrial septum is punctured and the device 
is delivered into the LAA in order to close it off from the rest of the left atrium. The three 
most prominent examples of these devices are the PLAATO device, the WATCHMAN 
12 
 
device and the Amplatzer Cardiac Plug. The PLAATO device (Figure 1.4.2A) consists of 
a self-expanding nitinol cage, with a diameter range of 15-32 mm, that expands to fill the 
volume of the LAA. It also has three rows of anchors along its struts to help fix it in 
place52. The WATCHMAN device (Figure 1.4.2C) also consists of a self-expanding 
nitinol frame with fixation barbs, and is covered by a permeable polyester fabric. It 
comes in diameters of 21, 24, 27, 30 and 33 mm53. The Amplatzer Cardiac Plug (Figure 
1.4.2B) is another nitinol mesh structure, but it is made of a distal lobe and a proximal 
disk with polyester patches sewn on, connected by a short waist. It acts like a pacifier 
with the distal lobe in the LAA and the proximal disk covering the orifice. It also has 
stabilizing hooks and comes in lobe sizes of 16-30 mm, in 2 mm increments54. 
 
Figure 1.4.2 Three percutaneous LAA occlusion devices5. A) The PLAATO device, B) 
The Amplatzer Cardiac Plug and C) The WATCHMAN device. 
 These devices seem like a promising solution for LAA closure, but there are many 
studies pointing out some of their drawbacks. In 2007, Onalan and Crystal reviewed data 
from the three aforementioned devices, and found a relatively high rate of complications. 
Out of 313 patients occluded with the PLAATO device, there were eight cases of 
pericardial effusion and nine cases of cardiac tamponade. With the WATCHMAN 
device, out of 66 patients there were five cases of pericardial effusion and two cases of 
device embolization. The Amplatzer Cardiac Plug was used in 16 patients, with one case 
of device embolization. In total, among these three devices, there were 31 major 
complications in 395 patients (8%)55. Holmes and Schwartz noted that percutaneous LAA 
occlusion devices carry potential procedural risks including air embolism from the 
placement of large sheaths, device embolization, pericardial effusion and vascular access 
13 
 
events. They concluded that the most significant complication is pericardial effusion, 
which can in rare cases lead to tamponade47. Another review looked at two studies done 
with the WATCHMAN device, and found that procedure or device related adverse events 
occurred within a week of device implantation in 6.5% of cases in one study and in 3.7% 
in the other. This included incidences of serious pericardial effusion in 5.0% and 2.2% of 
cases56. Yet another review, done last year, evaluated total adverse event rates for these 
three devices. The adverse event rate for the PLAATO device, the WATCHMAN device 
and the Amplatzer Cardiac Plug was 5.4%, 13.6% and 23.5%, respectively57. The most 
common complication with the PLAATO device is tamponade. With the WATCHMAN 
device, device embolization is a concern. The Amplatzer Cardiac Plug carries a risk of 
pericardial effusion, device thrombosis and embolization, and procedural stroke58. It is 
important to note that the PLAATO device is no longer clinically available for LAA 
occlusion59. So while these devices show promise as a relatively simple method for LAA 
occlusion, there are some disadvantages. Firstly, much more work needs to be done to 
ensure their safety. Secondly, it has been shown that their stroke reduction rates are more 
modest than initially reported, putting into question their effectiveness for patients with 
AF58. Finally, these devices have a uniform shape while the morphology of the LAA is 
extremely variable, limiting their ability to fully occlude the appendage. Currently, 
surgical LAA closure is still a better option than percutaneous device occlusion. 
1.4.3 LAA Exclusion 
 Exclusion of the LAA is the first of two broad categories of surgical LAA 
obliteration. The idea is to close off, or exclude, the LAA from the rest of the left atrium, 
effectively eliminating it and its thrombogenic potential5. The orifice of the LAA is 
closed using sutures or surgical staples (Figure 1.4.3). In 1984 and 1988, two separate 
automatic surgical staplers were introduced for exclusion of the LAA. Both studies 
reported adequate appendage obliteration and no complications60,61. The LAA orifice can 
also be sewn closed from within the left atrium using a pursestring suture62, and 
encircling suture51, or a double row of running suture48,51,63. More recently, a device 
called the AtriClip has been introduced for LAA exclusion in patients undergoing median 
sternotomy. The AtriClip is carefully placed over the LAA and clips it shut. It has 
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successfully closed the LAA in 67 of 70 
(96%) patients64. In 2012 a similar 
device, called the TigerPaw system, was 
introduced to epicardially exclude the 
LAA and was deemed safe after use in 
60 patients65.  
 However, LAA exclusion is not 
successful if post-operatively there is 
still some blood flow between the LAA 
and the left atrium. The presence of residual flow across the suture or staple line makes 
the operation a failure, since it the LAA remains a potential site of thrombogenesis5. 
Lynch and colleagues described six cases of patients who had undergone LAA exclusion 
by pursestring closure and subsequently experienced recanalization and high-velocity 
blood flow between the LAA and left atrium, as detected by TEE62. In 2000, Katz and 
colleagues used TEE to assess residual blood flow between the LAA and left atrium in 50 
patients who had undergone LAA suture exclusion. They found that 18 of these patients 
(36%) had incomplete LAA closure, and suggested that residual flow between the 
incompletely excluded LAA and the left atrium may produce a setting for stagnant blood 
within the appendage and may be a mechanism for thrombogenesis48. Another study 
assessed LAA exclusion, by surgical staple and by suture, in patients undergoing 
coronary artery bypass grafting. It found that exclusion was successful in only 24 of 33 
(72%) patients who had undergone staple exclusion, and in 5 of 11 (45%) patients who 
had undergone suture exclusion51. Schneider and colleagues (2005) evaluated six patients 
who underwent LAA exclusion by TEE and found that only one of them had a 
completely ligated LAA post-operatively. They also noted that incomplete closure results 
in blood stagnation in the LAA and increased likelihood of clot formation63. Finally, in 
2008 Kanderian and colleagues conducted another study assessing the success of both 
staple and suture exclusion by TEE. Only 17 of 73 (23%) suture LAA exclusions were 
successful, and out of 12 staple exclusions, none were a success66. There has been 
speculation as to why exclusion of the LAA fails so often, with the main cause being 
dehiscence of the sutures or staples due to tension from the LAA orifice as it attempts to 
Figure 1.4.3 Staple and suture exclusion 
of the left atrial appendage (LAA)5. 
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return to its original shape. These discouraging results illustrate the fact that current 
exclusion methods are not ideal for completely ligating the LAA. 
1.4.4 LAA Excision 
 Excision of the LAA is the second broad category of surgical LAA obliteration. It 
involves cutting off and removing the LAA completely and sewing the remnant shut5 
(Figure 1.4.4). In 1949, Madden published one of the first reports on removal of the LAA 
after performing it in two patients67. Johnson and colleagues (2000) performed LAA 
excision in 391 patients and recommend prophylactic LAA removal whenever a patient’s 
chest is open, in order to prevent potential thromboemboli from future development of 
atrial fibrillation19. An amputating stapler device can be used to excise the LAA and 
staple the remnant closed66,68, but it is more commonly performed with scissors66. In 
2010, Roth and colleagues introduced 
a technique for LAA excision that 
involved using a piece of the patient’s 
pericardium to reinforce the remnant 
in order to increase the safety of the 
procedure69. 
 Because the appendage is fully 
removed and not just excluded, 
residual flow between the LAA and 
the left atrium is not a concern in LAA 
excision. In an editorial comment in 
2011, Sievers noted that LAA excision has better outcomes than exclusion and mentioned 
that he has switched his technique for surgical LAA obliteration to complete excision70. 
Also in 2011, Chatterjee and colleagues published a review of LAA occlusion techniques. 
In the review they mention that epicardial excision with oversew is the most effective 
technique for surgical LAA closure, and that it is their method of choice5. 
 Despite excision being the current gold standard for surgical obliteration of the 
LAA, it is still not always successful. Excision is considered to be a failure if it fails to 
Figure 1.4.4 Epicardial excision with 
oversew of the left atrial appendage5. 
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remove the entire appendage and leaves a residual stump. Crystal and colleagues (2003) 
first put the criterion for what constitutes a residual stump forward in the Left Atrial 
Appendage Occlusion Study (LAAOS)71. Their criterion was a remnant LAA 1 cm in 
length or longer, and this was based on the rationale that the smallest appendages are 2 
cm long and a greater than 50% reduction in its volume would be necessary to reduce 
stroke risk. Now throughout the literature, a residual stump of 1 cm or greater is 
considered a failure66. This is important because one study found that residual stump left 
after LAA excision is potentially even more dangerous, in terms of stroke risk, than the 
initial appendage6. A reason for this is not cited, but there is speculation as to why this is 
the case. The idea is that in an intact LAA thrombi form in the tip and are rarely 
dislodged, while in a shallower residual stump, thrombi form near the orifice and are 
much more likely to be dislodged by the flow of blood through the heart and embolize. In 
one study of 52 patients who underwent LAA excision, a residual stump greater than 1 
cm was present in 14 of them, resulting in a success rate of 73%66. Therefore, while LAA 
excision is the current gold standard, and generally much more successful than exclusion, 
it can still leave a residual stump limiting its effectiveness and presenting a potential 
danger to patients.  
1.4.5 Circumflex Coronary Artery 
 As mentioned earlier, the circumflex artery is a branch of the left main coronary 
artery, as is the anterior interventricular artery. After it branches, it curves down and 
around the base of the LAA epicardially, running in the left coronary sulcus towards the 
posterior of the heart8. It supplies blood to the left atrium and the posterolateral part of 
the left ventricle8. Because of its close proximity to the base of the LAA, it has been 
noted several times that the circumflex artery is in danger of being injured during surgery 
on the appendage, epicardially and even endocardially7,10,12,72. Because of its area of 
supply, damage to this artery would interrupt blood flow to the left atrium and part of the 
left ventricle, causing significant damage. Although the potential danger is recognized, no 
comprehensive measurements of the distance between the artery and the LAA have been 
made. 
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1.4.6 Pericardial Patch Exclusion of the LAA 
 All of the current surgical options for LAA closure have their drawbacks, and in 
many cases these disadvantages can put patients at great risk. It is important that a safe 
and effective technique of completely closing the left atrial appendage is found, in order 
to reduce stroke risk in patients with atrial fibrillation. The ideal LAA surgical closure 
method would fulfill certain criteria. Firstly, it would fully and completely eliminate the 
appendage, leaving no residual stump. Secondly, it would not allow residual 
communicative blood flow between the LAA and the left atrial cavity. Thirdly, it would 
be able to be performed with minimal strain on the patient, and with minimal chance of 
perioperative and post-operative complications. Fourthly, it would not require the patient 
to be on medication post-operatively. Finally, it would comfortable suit the size and 
shape of any individual’s left atrial appendage. 
With this in mind, Dr. Michael W.A. Chu MD, FRCSC, a cardiac surgeon at London 
Health Sciences Centre in London, Ontario, Canada, has developed a novel method of 
surgical LAA obliteration called ‘pericardial patch exclusion’ that shows promise in 
being able to completely close the LAA. The technique involves resecting a piece of the 
patient’s pericardium and shaping it to the individual’s LAA orifice. The patch is then 
sewn over the orifice using a running suture, excluding the appendage from the rest of the 
left atrium. The idea is that this technique can overcome the failures of conventional 
excision and exclusion. It should not leave any residual LAA volume, since the patch 
covering the orifice is level with the atrial wall. Also, there will hopefully be no residual 
blood flow between the appendage and the left atrium since the patch does not deform the 
LAA orifice, reducing the potential for dehiscence of the sutures. Using a cadaveric 
model we can assess residual LAA volume left by these methods, but we cannot assess 
blood flow across the patch or the suture line. 
1.5 Rationale Statement 
This research aims to fulfill three goals. The first is to provide an anatomical 
description of the left atrial appendage in order to guide the development of more 
effective closure methods. Percutaneous devices that are currently used to close the LAA 
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work by expanding and filling the appendage and blocking off the orifice. However, 
these devices are available in a limited range of sizes, which may exclude some 
individuals. Determination of the range of LAA and LAA orifice sizes may provide 
valuable information to help ensure that all patients have closure devices available to 
them. 
The second aim is to determine the distance between the circumflex coronary 
artery and the LAA at specific points around its base. The circumflex is in danger during 
any LAA surgery, but little is known about the specific regions that require most 
attention, or how far the artery is from the base of the LAA. These results will give 
physicians an idea of which areas require more care and attention, and will hopefully 
reduce the incidence of injury to the artery. Also, the branching of the left main coronary 
artery to the LAD and the circumflex occurs at a variable position. Measuring at which 
point this branching is most likely to occur will provide useful information in terms of 
how extensive ischemic injury may be when damage occurs at a certain point.  
The third and final aim is to evaluate the novel pericardial patch exclusion method 
of LAA closure in comparison to conventional epicardial excision, with regards to 
residual volume left in the appendage after each operation. Epicardial excision is the 
current gold standard for surgical LAA closure. However, it often leaves a potentially 
thrombogenic residual stump. Pericardial patch exclusion shows promise in fully 
eliminating the LAA. Pericardial patch exclusion, if it leaves little or no residual LAA 
volume, may be a viable option for surgical LAA closure, and may help reduce stroke 
risk in patients with atrial fibrillation. 
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1.6 Objectives 
Using a cadaveric model, the objectives of this investigation are: 
1. To provide a full and accurate description of the anatomical dimensions of the left 
atrial appendage (LAA) to accommodate the development of more effective 
closure methods.  
2. To track the course of the circumflex artery around the base of the LAA and to 
measure its proximity at various points. This will give surgeons a better idea in 
which area the circumflex artery in greatest danger of being injured, and where to 
be most careful, during LAA operations. 
3. To assess the residual volume left in the LAA by conventional epicardial excision 
and by the novel pericardial patch exclusion technique, as compared to the initial 
LAA volume. This will help determine if pericardial patch exclusion is a more 
effective method for eliminating the LAA, and whether it is a viable option for 
surgical LAA closure. 
 
1.7 Hypothesis 
With regards to the third objective of this project, it is hypothesized that the novel 
pericardial patch exclusion technique will leave less residual volume in the left atrial 
appendage than conventional epicardial excision. 
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Chapter 2  
2 Methods 
2.1 Subject Data 
 A total of 27 adult cadaveric hearts were harvested from specimens in the Human 
Anatomy Lab at Western University in accordance with the Anatomy Act of Ontario and 
Western’s Committee for Cadaveric Use in Research, approval #15052013. Of these 27 
cadaveric, 18 (67%) were from specimens fixed with a 10% formalin solution, and nine 
(33%) were from fresh frozen specimens. Mean age of all 27 specimens was 77.1 ± 12.5 
(53-97) years and consisted of 18 (67%) male and 9 (33%) female donors. Mean age of 
the formalin fixed specimens (n=18) was 79.8 ± 12.3 (53-97) years and consisted of 11 
(61%) male and 7 (39%) female donors. Mean age of the fresh frozen specimens (n=9) 
was 71.8 ± 12.5 (55-87) years and consisted of 7 (78%) male and 2 (22%) female donors. 
Full subject data is available in Table 2.1.1 
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Table 2.1.1 Subject characteristics. 
 SEX AGE CAUSE OF DEATH 
 
 
 
 
 
 
 
 
Formalin 
Fixed 
 
 
 
 
 
 
 
 
M 84 Cardiac Arrest, Heart Failure, Coronary Artery Disease 
M 93 Bladder Cancer, COPD 
M 63 Cardiac Arrhythmia, Complicating COPD 
F 78 Diffuse Metastatic Cancer,  Ulcerative Colitis 
F 90 Pneumonia, Progressive Supranuclear Palsy 
F 75 Multiple Myeloma, Chronic Renal Failure 
M 85 Cerebrovascular Accident, COPD, Periph Vascular Disease 
F 76 Non-Alcoholic Liver Cirrhosis, Atrial Fibrillation, ASHD 
M 62 Metastatic Melanoma, Melanoma 
F 93 Breast Cancer, Parkinsons Disease 
M 97 Dehydration, Bowel Obstruction, Fecal Impaction, CVA 
M 87 Fractured Left Hip, Cancer of the pancreas 
M 69 End Stage Chronic Obstructive Lung Disease 
F 89 CVA, COLD, Congestive Lung Failure 
M 53 Carcinoma of the Bladder 
F 73 Breast Cancer 
M 80 Parkinsons Disease, illegible, Ischemic Heart Disease 
M 90 Pneumonia, Depression, Ischemic Heart Disease 
 
 
 
Fresh 
Frozen 
M 55 Possible Pneumonia, Severe COPD, Lung Cancer 
M 79 Coronary Artery Disease, Diabetes, Sudden Cardiac Arrest 
M 87 Coronary Artery Disease, Congestive Heart Failure, A Fib 
F 70 Brain Metastases, Lung Cancer, Breast Cancer 
M 65 Cardiac Arrest, Coronary Artery Disease, Bladder Cancer 
M 84 Acute Uremia, Dementia, Chronic Obstructive Lung Disease 
M 66 Acquired Brain Injury 
F 55 Pneumonia, Right pan coast Lung Tumor 
M 85 Cancer of the Lung, Dementia 
 
 
 
 
 
 
 
22 
 
2.2 Study Design 
 The study protocol was carried out on all (n=27) cadaveric hearts. The hearts were 
dissected epicardially in order to expose the circumflex artery, and the posterior aspect of 
the wall of the left atrium was cut in order to expose the left atrial cavity and visualize the 
LAA orifice. Various dimensions of the LAA and the LAA orifice were then measured. 
Next, the proximity of the circumflex artery was measured at six points around the base 
of the LAA. Finally, the hearts underwent pericardial patch exclusion and epicardial 
excision, after each of which residual volume was measured. 
2.3 Measurement of the LAA 
 The length of each LAA was measured from the centre of the base to the most 
distal tip. Width was measured at the widest part of the appendage, perpendicular to the 
axis of length (Figure 2.3.1A). The measurements carried out on the LAA orifice were 
the length of the major axis, length of the minor axis and circumference (Figure 2.3.1B). 
The LAA orifice is oval in shape, so the major axis is its longest diameter (in the vertical 
plane) and the minor axis is its shortest diameter (in the horizontal plane). LAA volume 
was also measured. All measurements except for LAA orifice circumference and LAA 
volume were made once with a ruler and once with a digital Vernier caliper (Procise 
Digital Caliper, 6 inch, model 210-2373), each by two raters. LAA circumference was 
measured to the nearest 1 cm with a string and ruler by two different raters. LAA volume 
was measured to the nearest 0.1 mL twice, once by filling it to the orifice with water and 
recording the volume of water used, and again by filling it to the orifice with agarose gel, 
waiting for the gel to harden, then removing the gel and submerging it in water and 
recording the volume change of the water.  
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Figure 2.3.1 A) Measurements carried out on the LAA included length, width and 
volume, B) and measurements carried out on the LAA orifice included major axis, minor 
axis and circumference. 
 
2.4 Measurement of the Proximity of the Circumflex 
Artery 
 When viewing the LAA orifice from inside the left atrial cavity, surgeons use an 
imaginary superimposed clock face to refer to different positions around its edge. The 
clock face is arranged so that the 12 o’clock and 6 o’clock positions lie at either end of 
the major axis, and 3 o’clock and 9 o’clock lie at either end of the minor axis. When 
translated from the endocardial aspect of the heart to the epicardial side, the clock face is 
flipped and ends up arranged in a counter clockwise orientation (Figure 2.4.1). This 
reflected clock, from 12 o’clock to 6 o’clock, was drawn around the base of the LAA 
with a marker as accurately as possible. The distance from the base of the LAA at each of 
these seven equidistant points (12, 1, 2, 3, 4, 5 and 6 o’clock) to the nearest edge of the 
circumflex artery, or the left main coronary artery prior to the branching of the 
circumflex, was measured. All measurements were made once with a ruler and once with 
a digital Vernier caliper (Procise Digital Caliper, 6 inch, model 210-2373), each by two 
raters. 
 
24 
 
 
 
 
Figure 2.4.1 Endocardial and epicardial view of clock-face arrangement used to orient 
the LAA orifice. 
 
2.5 Surgical Techniques 
 All surgeries were performed by board certified cardiac surgeons. Pericardial 
patch exclusion was performed first. Excess pericardial tissue was obtained from the 
Human Anatomy Lab at Western University, and patches were cut to the shape of each 
individual LAA. The patches were then sewn over the orifice of the LAA using a running 
4-0 prolene suture. After the patch was in place, residual volume in the appendage was 
measured in the same way initial LAA volume was, once with water and once with 
agarose gel. After volume was measured, the suture was cut and the patch was removed. 
Conventional epicardial excision was then performed on each heart. Using scissors, the 
LAA was resected as close as possible to its base without risking coronary injury or 
hemorrhage. The remnant stump was then sutured shut using a running 4-0 prolene 
suture. After the excision was complete, residual volume was once again measured by 
water and by agarose gel.  
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Figure 2.5.1 Pericardial patch exclusion of the LAA, showing the original orifice and the 
patch sewn in place. 
 
Figure 2.5.2 Epicardial excision of the LAA, showing the original appendage, the 
excised portion and the remnant sewn shut. 
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Chapter 3  
3 Results 
3.1 Statistical Analysis 
Data were imported and analyzed using SPSS software version 22 (IBM Corp., 
Armonk, NY, USA, 2013). Continuous data are presented as mean ± SD. A 
nonparametric one-way ANOVA was performed to determine if the residual volumes left 
by the two LAA closure methods were different, and p values < 0.05 were considered 
significant. Most measurements were made by digital Vernier caliper to the nearest 0.01 
mm as well as by ruler to the nearest 1 mm. Because of this discrepancy, parallel-forms 
reliability was performed in order to determine the agreement between the two methods. 
The resulting reliability was 0.993, so it was deemed appropriate to proceed using only 
the data from the digital Vernier caliper measurements. Inter-rater reliability was 0.994. 
Parallel-forms reliability was done to compare the volume measurement with water and 
with agarose gel and the reliability was 0.997.  
3.2 Measurements of the LAA 
 The mean length, width and volume of the LAA are shown in Table 3.2.1. Along 
with the overall information (n=27), the data is separated into formalin fixed specimens 
only (n=18) and fresh frozen specimens only (n=9). This is done to show general trends; 
no statistical analysis was carried out regarding the differences between the groups. 
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Table 3.2.1 Mean length (mm), width (mm) and volume (mL), SD and range in all hearts 
(n=27), formalin fixed (n=18) and fresh frozen (n=9). 
 
The mean dimensions of the LAA orifice, major axis length, minor axis length 
and circumference, are shown in Table 3.2.1. Again, the information (n=27) is stratified 
into fixed (n=18) and fresh (n=9) specimens to show general trends. 
 
Table 3.2.2 Mean LAA orifice major axis, minor axis and circumference (mm), SD and 
range in all hearts (n=27), formalin fixed (n=18) and fresh frozen (n=9). 
 
 All Hearts (n=27) Formalin Fixed (n=18) Fresh Frozen (n=9) 
 Major 
Axis 
(mm) 
Minor 
Axis 
(mm) 
Circum. 
(mm) 
Major 
Axis 
(mm) 
Minor 
Axis 
(mm) 
Circum. 
(mm) 
Major 
Axis 
(mm) 
Minor 
Axis 
(mm) 
Circum. 
(mm) 
Mean 23.03 14.20 64.39 22.79 12.08 58.94 23.50 18.44 75.28 
SD 5.94 5.52 22.24 5.72 3.76 13.86 6.68 6.20 31.62 
Minimum 11.93 6.51 28.00 14.85 6.54 39.00 11.93 6.51 28.00 
Maximum 37.57 28.98 128.50 37.57 22.30 86.50 34.65 28.98 128.50 
 
 All Hearts (n=27) Formalin Fixed (n=18)    Fresh Frozen (n=9) 
 Length 
(mm) 
Width 
(mm) 
Volume 
(mL) 
Length 
(mm) 
Width 
(mm) 
Volume 
(mL) 
Length 
(mm) 
Width 
(mm) 
Volume 
(mL) 
Mean 41.06 29.13 4.02 38.84 30.86 3.17 45.49 25.67 5.73 
SD 12.80 8.01 4.01 9.50 8.25 3.70 17.54 6.58 4.26 
Minimum 23.34 15.76 0.25 24.15 20.67 0.55 23.34 15.76 0.25 
Maximum 78.69 52.26 16.80 58.02 52.26 16.80 78.69 34.21 13.30 
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3.3 Proximity of the Circumflex Artery to the Base of 
the LAA 
The mean distance from either the left main coronary artery or the circumflex 
artery to the base of the LAA at each point around the clock-face is shown in Table 3.3.1. 
The artery was closest to the base of the LAA at the 3:00, 4:00 and 5:00 positions. The 
mean distance of the artery to the LAA, ± two SD, is also shown in Figure 3.3.1. 
Table 3.3.1 Mean distance from left main or circumflex artery to base of LAA (mm), SD 
and range at each point around clock-face (12:00 to 6:00). 
 12:00 1:00 2:00 3:00 4:00 5:00 6:00 
Mean (mm) 15.31 11.44 8.89 6.90 5.94 6.54 8.38 
SD (mm) 4.44 3.57 2.50 1.92 1.29 1.87 2.16 
Minimum (mm) 8.81 6.60 5.43 3.86 3.92 3.75 5.16 
Maximum (mm) 22.73 18.47 13.89 10.55 9.29 11.78 12.49 
 
 
Figure 3.3.1 Mean distance from artery to the base of LAA (mm), ± 2 SD, at each point 
around clock-face (12:00 to 6:00). 
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 Whether the artery that was closest to the base of the LAA at each point around 
the clock-face was the left main coronary artery (LM) or the circumflex artery (Cx) is 
shown in Table 3.3.2. At 12:00 and 1:00, the artery closest to the LAA was usually the 
left main. At 2:00 and 3:00, the artery closest to the LAA was most often the circumflex. 
At 4:00, 5:00 and 6:00, the artery closest to the LAA was always the circumflex. This 
information is also shown in Figure 3.3.2. 
Table 3.3.2 Identity of the artery closest to the base of the LAA, left main (LM) or 
circumflex (Cx), at each point around the clock-face (12:00 to 6:00). 
 12:00 1:00 2:00 3:00 4:00 5:00 6:00 
# Closer to LM 23 18 8 3 0 0 0 
# Closer to Cx 4 9 19 24 27 27 27 
Closer to LM 85.2 % 66.7 % 29.6 % 11.1 % 0 % 0 % 0 % 
Closer to Cx 14.8 % 33.3 % 70.4 % 88.9 % 100 % 100 % 100 % 
 
 
Figure 3.3.2 Identity of the artery closest to the base of the LAA, left main (LM) or 
circumflex (Cx), at each point around the clock-face (12:00 to 6:00). 
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3.4 Residual Volume Left by Epicardial Excision and 
by Pericardial Patch Exclusion 
 The mean volume of the LAA prior to any intervention, mean volume after 
conventional epicardial excision and mean volume after pericardial patch exclusion is 
shown in Table 3.4.1. This data is also stratified further into formalin fixed specimens 
and fresh frozen specimens. This information is also shown in Figure 3.4.1. 
Table 3.4.1 Mean volume (mL) ± SD and residual volume (%) in the LAA prior to 
intervention, after conventional epicardial excision (CEE) and after pericardial patch 
exclusion (PPE), in all hearts (n=27), fixed specimens (n=18) and fresh specimens (n=9). 
 
  Original LAA After CEE After PPE 
 
All Hearts  
(n=27) 
Volume (mL) 4.02 ± 4.01 0.95 ± 1.02 0.17 ± 0.08 
% Residual - 23.63 % 4.23 % 
 
Formalin Fixed  
(n=18) 
Volume (mL) 3.17 ± 3.70 1.11 ± 1.13 0.19 ± 0.10 
% Residual - 35.02 % 5.99 % 
  
Fresh Frozen Volume (mL) 5.73 ± 4.26 0.62 ± 0.71 0.14 ± 0.05 
(n=9) % Residual - 10.82 % 2.44 % 
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Figure 3.4.1 Mean volume (mL) ± SE in the LAA prior to intervention, after 
conventional epicardial excision (CEE) and after pericardial patch exclusion (PPE), in all 
hearts (n=27), fixed specimens (n=18) and fresh specimens (n=9). (*) indicates 
significant difference in LAA volume (p<0.05). 
 There was a significant effect of LAA condition (prior to intervention, after CEE, 
or after PPE) on volume in the LAA [χ2(2)=57.35; p<0.05; 1-β>0.8]. Post hoc 
comparisons indicated that the mean volume of the LAA prior to intervention, the mean 
LAA volume after CEE, and the mean LAA volume after PPE were all significantly 
different. Therefore, conventional epicardial excision left a significantly greater residual 
volume in the LAA than pericardial patch exclusion did. The data for the two stratified 
groups (formalin fixed specimens and fresh frozen specimens) was not analyzed because 
of a lack of power due to small sample sizes. 
 
0
1
2
3
4
5
6
7
All Hearts (n=27) Fixed (n=18) Fresh (n=9)
Vo
lu
m
e 
(m
L)
 
Prior to Intervention
After CEE
After PPE* 
* 
* 
32 
 
Chapter 4  
4 Discussion 
4.1 Interpretation of Results 
This investigation aimed to use a cadaveric model to fulfill three objectives 
regarding the left atrial appendage (LAA). The first objective was to produce a 
description of the anatomical dimensions of the appendage. According to the results of 
this study, the mean length of the LAA was 41.06 ± 12.80 mm, the mean width was 29.13 
± 8.01 mm, and the mean volume was 4.02 ± 4.01 mL. In terms of the LAA orifice, the 
mean major axis diameter was 23.03 ± 5.94 mm, the mean minor axis diameter was 14.20 
± 5.52 mm, and the mean circumference was 64.39 ± 22.24 mm. 
The second objective was to measure the distance from the circumflex coronary 
artery to the base of the LAA at various points. The results showed that the artery was 
furthest away from the LAA at the 12 o’clock position, with a mean distance of 15.31 ± 
4.44 mm. Moving around the base of the LAA in a counter-clockwise direction, the 
artery got progressively closer to the appendage. It reached its closest proximity at the 4 
o’clock position, with a mean distance of 5.94 ± 1.29 mm. From then on the distance 
began to grow once again.  
The third objective was to evaluate a novel method of LAA closure in comparison 
to current standards. The novel method, pericardial patch exclusion, was hypothesized to 
leave less residual LAA volume than the conventional epicardial excision technique. The 
mean volume remaining in the LAA following epicardial excision was 0.95 ± 1.02 mL. 
Pericardial patch exclusion left a mean residual volume of 0.17 ± 0.08 mL, which is 
significantly smaller (p<0.05). These results are in accordance with our hypothesis.  
4.2 Clinical Implications 
The LAA is an area of great interest in cardiac surgery because of its implications 
with stroke risk in patients with atrial fibrillation (AF). Because of this, the findings of 
this study have numerous clinical implications. 
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4.2.1 Dimensions of the LAA 
There have been several studies to note the great variability in the size and shape 
of the LAA11,12,14,15, and that variety has been found in this investigation of 27 cadaveric 
hearts as well. The length of the LAA ranged from 23.34 mm to 78.69 mm, the width 
ranged from 15.76 mm to 52.26 mm, and the volume ranged from 0.25 mL to 16.80 mL. 
The major axis of the orifice ranged from 11.93 mm to 37.57 mm, the minor axis ranged 
from 6.51 mm to 28.98 mm, and the circumference ranged from 28.0 mm to 128.5 mm. 
These huge ranges are indicative of the considerable differences from one LAA to the 
next. This is of clinical importance because percutaneous LAA occlusion devices 
function by expanding and filling the appendage. They must completely fill the LAA and 
fully cover the orifice in order to be effective. The three most prominent such devices are 
the PLAATO device, the WATCHMAN device and the Amplatzer Cardiac Plug. These 
devices are available in different sizes, and are sized to the LAA orifice diameter of each 
patient. The PLAATO device comes in diameter sizes that range from 15-32 mm52. The 
WATCHMAN device comes in a diameter range of 21-33 mm53. The Amplatzer Cardiac 
Plug is available in sizes ranging from 16-30 mm54. So these devices are only designed to 
safely fit in a LAA orifice that is no smaller than 15 mm and no larger than 33 mm. 
However, in this study alone, orifice diameter ranged from 7 mm to 38 mm. It is likely 
that there are a considerable number of individuals for whom these devices would either 
be too small or too large, negatively affecting their effectiveness and their safety. This 
information may serve to drive the development of LAA occlusion devices with a larger 
selection of sizes to fit more patients. Conversely, surgical techniques of LAA closure are 
not limited by appendage size. Pericardial patch exclusion, notably, is designed to be 
customizable to the size of each individual LAA orifice. 
4.2.2 Proximity of the Circumflex Artery 
The close proximity of the circumflex coronary artery to the base of the LAA 
places it in danger during operation on the appendage7,10,12. This is not only true for 
operations that take an epicardial approach such as excision. It is also true for endocardial 
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operations, such as suture or staple exclusion, and even implantation of percutaneous 
closure devices72. Part of this investigation included measuring the distance from the 
edge of the artery to the base of the LAA at seven different points. Cardiac surgeons use a 
clock-face arrangement to refer to different parts of the LAA orifice, and this clock-face 
was transferred over to the epicardial aspect of the heart. The seven points of 
measurement were determined from the 12 o’clock through 6 o’clock positions. The 
results, as found in Table 3.3.1, indicate that the artery is relatively far from the LAA at 
the 12 o’clock position, but begins to get closer at 1 and 2 o’clock. The artery is closest at 
3, 4 and 5 o’clock, but then begins to course away again at 6 o’clock. This suggests that 
during any intervention on the LAA, special care must be taken when the 3, 4 or 5 
o’clock positions are involved. These are the points at which the circumflex artery is at 
greatest risk. 
 Moreover, as seen in Figure 3.3.1, the mean distance of the artery was plotted on 
a line graph along with a line indicating the mean minus two standard deviations and a 
line indicating the mean plus two standard deviations. This was done because 95% of 
values lie within two standard deviations from the mean. So this line graph represents a 
“95% zone” wherein an artery would be expected to lie in 95% of cases. Paying special 
attention to the line representing the mean minus 2 SD, one can see that although on 
average the artery is a comfortable distance from the base of the LAA at 12, 1 and 2 
o’clock, the 95% zone extends to much closer. In fact, the only real safe zone lies within 
3 mm of the base of the LAA. This is also very important for physicians to consider. 
Although they may rightfully expect to encounter the artery at 3, 4 and 5 o’clock, they 
must also be prepared to see it as close as 4 mm from the LAA at other points. Previous 
studies have mentioned the risk of injuring the circumflex artery during LAA 
surgeries7,10,12, but none have attempted to directly measure the proximity of the artery to 
the base of the LAA. This is the first investigation to track the distance from the artery to 
the appendage at various points, using surgical nomenclature to provide a clinically 
relevant account of its course around the LAA. 
 Furthermore, it is not always the circumflex artery proper that is closest to the 
base of the LAA; sometimes it is the left main coronary artery. As seen in Table 3.3.2 and 
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Figure 3.3.2, at the 12 and 1 o’clock positions the artery that was closest to the LAA was 
most often the left main. At 2 and 3 o’clock one was more likely to see the circumflex 
artery, and from 4 to 6 o’clock it was always the circumflex that was closest. This has 
implications with regards to the interruption of blood supply in the event of injury to the 
artery. Damage near the 12, 1 and 2 o’clock positions would be more likely to involve the 
left main artery, and that would affect blood flow through the anterior interventricular, or 
left anterior descending (LAD), artery as well as the circumflex. The circumflex artery 
supplies blood to the left atrium and the posterolateral left ventricle. The LAD supplies 
blood to the IV septum, the apex of the heart, and approximately half of the left 
ventricle8. Therefore, during an operation on the LAA, damage to the artery after the 2 
o’clock position would likely affect blood flow to the left atrium and the posterolateral 
aspect of the ventricle. Conversely, damage to the artery prior to this point may affect 
blood flow to the left atrium, the entire left ventricle and part of the IV septum, producing 
a much more dire situation. 
4.2.3 Surgical Closure of the LAA 
For patients with AF, the vast majority of blood clots that form in the heart come 
from the LAA4. Because of this, surgical closure of the LAA can be performed, and is 
done either by exclusion or by excision. Excision is the more popular method5,70, but it 
can leave a stump with residual volume within, which may be even more thrombogenic 
and dangerous6. A novel method of LAA closure, called pericardial patch exclusion, has 
been developed in order to overcome this. The patch of pericardium is sutured over the 
patient’s LAA orifice flush with the left atrial wall, so it should leave very little residual 
volume, if any. In this investigation, 27 cadaveric hearts underwent both conventional 
epicardial excision (CEE) of the LAA as well as pericardial patch exclusion (PPE) to 
evaluate which method left less residual volume. CEE was found to have reduced the 
volume of the LAA to 0.95 ± 1.02 mL (24% of the original), while PPE reduced the LAA 
volume to 0.17 ± 0.08 mL (4% of the original). Therefore, PPE left a significantly 
smaller residual LAA volume than CEE, suggesting that it may improve stroke risk in 
patients with AF.  
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While the formalin fixation process does not change the size of tissues, it does 
change their properties. Formalin acts by cross-linking proteins in the treated specimens, 
and because of this tissue that has been fixed with formalin is generally stiffer and less 
compliant than fresh tissue. Fresh cadaveric tissue is more comparable to the live tissue 
that would be encountered in surgery. For this reason, the data from the surgical 
interventions was stratified into two groups, fixed specimens (n=18) and fresh specimens 
(n=9). While the same trends that are seen in the overall group (n=27) are seen in both 
stratified groups, the difference in residual volume left after CEE and after PPE is smaller 
in the fresh specimen group. CEE managed to remove more of the LAA in this group, 
probably due to the compliant nature of the tissue. Also, due to the nature of the study, 
the LAA was more visible and more accessible than it would be in a real surgery. Due to 
the small sample size of the fresh group, analysis was not carried out on the difference 
between CEE residual volume and PPE residual volume because there was not enough 
power to detect significance. According to power a priori power calculations, a sample 
size of 15 fresh specimens would be required to achieve the power to detect significance. 
So the collapsed overall results are considered. 
According to the results of this investigation, pericardial patch exclusion left a 
very minimal residual LAA volume of 0.17 ± 0.08 mL. However, the patch that was 
sewn over the orifice of the LAA appeared to be completely level with the wall of the 
surrounding left atrium. It is possible that because volume was measured using water and 
agarose gel, the residual volume that was observed was the result of the surface tension of 
these materials. Therefore, it may be the case that the actual residual volume left by 
pericardial patch exclusion was negligible, and that the LAA was virtually eliminated. 
Besides leaving less residual volume than epicardial excision, the pericardial 
patch exclusion technique of LAA closure has several other advantages. One is that it can 
be performed either via sternotomy or with a mini mally invasive approach, using a right 
minithoracotomy. Epicardial excision on the other hand can only be done via sternotomy. 
This is important because surgical occlusion of the LAA is often done concomitantly 
with mitral valve repair48, and mitral valve repair is frequently performed via a right 
minithoracotomy approach73.  
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The tissue of the left atrium, and especially of the LAA, is very delicate and 
friable. This can lead to tearing of the tissue and bleeding in LAA operations5,61,69. The 
fact that the LAA is not resected in pericardial patch exclusion nearly eliminates the risk 
of bleeding. Furthermore, the pericardium has previously been used as reinforcement for 
the thin and easily torn LAA tissue during excision procedures69. Similarly, our use of 
pericardium in the patch exclusion technique may attenuate the risk of bleeding from the 
delicate atrial tissue.  
Another advantage of pericardial patch exclusion over epicardial excision is that it 
leaves the appendage on the heart. The LAA plays an important role in the control of 
natriuresis through the secretion of atrial natriuretic peptide21,22,74. The fact that PPE 
leaves the LAA intact and attached might be beneficial because it may help maintain 
homeostatic regulation of natriuresis and diuresis. 
While excision of the LAA is deemed unsuccessful if there is a residual stump, 
exclusion methods are deemed unsuccessful if blood flow persists between the LAA and 
the left atrial cavity across the suture or staple line as detected post-operatively by 
transesophageal echocardiography (TEE) post-operatively48,66. Current exclusion 
techniques have a higher rate of failure than excision techniques5, and this failure may be 
the result of a couple of factors. Exclusion of the LAA involves bringing two sides of the 
orifice together and pursing the tissue of the left atrium. This may place tension on the 
sutures or staples as the orifice naturally begins to return to its original shape, causing 
dehiscence and recanalization of the LAA62. Additionally, because of the proximity of 
structures such as the circumflex artery that may be injured intra-operatively, shallow 
suture bites are often taken in order to avoid damaging these structures5. This may also 
lend to the dehiscence that leads to failure of LAA exclusion. Both of these obstacles are 
overcome by the pericardial patch exclusion technique. Because the patch is cut to the 
shape of the LAA orifice, the left atrial tissue does not become pursed or bunched, 
eliminating tension placed on the sutures. Also, owing to the longer suture line and lack 
of tension, smaller suture bites are more effective at holding the patch in place.  
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In recent years there has been development of several percutaneous LAA 
occlusion devices. While these devices show promise in effectively occluding the LAA, 
there are many potential risks with their use including device embolization, pericarditis, 
pericardial effusion, cardiac tamponade, and LAA tearing55,58. Also, their actual stroke 
reduction rates are more modest than anticipated55. As such, more investigation must be 
done before these devices can be used as reliable and effective alternatives to surgical 
closure of the LAA. The pericardial patch exclusion technique carries far fewer risks than 
these devices. Since the pericardium is not thrombogenic, as the percutaneous devices 
are, patients do not have to be placed on dual antiplatelet therapy post-operatively to 
prevent clotting. Also percutaneous occlusion devices rely on expanding and filling the 
LAA, but do not take into account the variable morphology of the appendage. Pericardial 
patch exclusion on the other hand involves covering the LAA orifice, making it suitable 
for any appendage morphology. 
All LAA closure methods have their strengths and their weaknesses. Four of these 
methods are compared in Table 4.2.3. In terms of the difficulty of performing each 
procedure, excision and exclusion are relatively easy to perform, while implantation of 
percutaneous devices and pericardial patch exclusion are more difficult. Excision and 
percutaneous device closure carry a risk of bleeding, while this risk is negligible for both 
conventional and pericardial patch exclusion. Infection and erosion are only a concern for 
percutaneous devices. Patients undergoing percutaneous device closure must remain on 
dual antiplatelet therapy for six months to prevent thrombogenesis from the device. This 
is not a concern in the other three methods. Finally, the approach that must be taken for 
each of the techniques is important. Percutaneous devices are introduced via catheter. The 
other three methods can be done after a sternotomy. However, only conventional and 
pericardial patch exclusion can be done with a minimally invasive approach. Looking at 
the risks and benefits of pericardial patch exclusion, it can be noted that the only 
disadvantage is that it is more difficult to perform. Aside from that, it seems to be a 
superior LAA closure technique. 
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Table 4.2.3 Comparison of four methods of LAA closure.  
 Conventional 
Epicardial 
Excision 
Conventional 
Endocardial 
Exclusion 
Percutaneous 
Device Closure 
Pericardial 
Patch 
Exclusion 
 
Difficulty 
 
+ 
 
+ 
 
+++ 
 
+++ 
 
Risk of Bleeding 
 
++ 
 
low 
 
+ 
 
low 
 
Risk of Infection 
 
0 
 
0 
 
++ 
 
0 
 
Risk of Erosion 
 
0 
 
0 
 
++ 
 
0 
 
Requirement of 
Additional 
Medications 
 
 
0 
 
 
0 
 
 
++ 
 
 
0 
 
Approach 
 
Sternotomy 
Sternotomy, 
Minimally 
Invasive 
 
Percutaneous 
Sternotomy, 
Minimally 
Invasive 
  
4.3 Strengths and Limitations 
There are several important strengths to this investigation. The use of cadaveric 
specimens allowed for direct measurements of the dimensions of the LAA, the proximity 
of the circumflex artery, and residual volume left after intervention. Almost all previous 
studies on LAA closure have relied on TEE to evaluate operational success, but because 
of the complex morphology and branching pattern of the LAA, TEE may not be 
completely accurate13. Also, the use of a cadaveric model made it possible for both 
interventional methods, CEE and PPE, to be performed in each specimen. This allowed 
each heart to serve as its own control, and effectively doubled the sample size. If a 
cadaveric model were not used, only one of the two intervention techniques could have 
been performed in each heart, requiring twice as many subjects to obtain the same results. 
Another strength of this study is that it is the first to measure the exact distance from the 
circumflex artery to the base of the LAA, and did so in terms understood by all cardiac 
surgeons. 
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This investigation also had some limitations that must be addressed. The first is 
the sample size of 27 cadaveric hearts. This relatively small sample size limits the 
robustness of the findings. Furthermore, the properties of fresh cadaveric tissue are more 
indicative of live tissue, but only nine fresh cadaveric hearts were available for this study. 
Another limitation is that the use of a cadaveric model precluded the assessment of 
residual blood flow or leakage between the LAA and the left atrium, which is the 
mechanism of failure for LAA exclusion techniques. Finally, this study data may have 
been limited by human error with respect to all of the measurements carried out.  
4.4 Future Directions 
The main priority of future investigations like this one should be access to a 
greater number of specimens. Increasing the sample size would increase the robustness 
and validity of the findings. This is especially true for fresh frozen specimens, since they 
are more comparable to state of the heart in a live patient. If more fresh specimens were 
involved in this study, it would likely be possible to detect a significant difference in the 
residual volume left by CEE and that left by PPE. Further investigation into the 
effectiveness of the pericardial patch exclusion method and its viability as an alternative 
to current standards of surgical LAA closure will have to involve evaluation of the 
technique in live patients. This would allow for assessment of persistent blood flow 
between the LAA and the left atrial cavity across the patch by transesophageal Doppler 
echocardiography or CT. Consideration of PPE as an improvement on current methods of 
LAA exclusion depends on the absence of post-operative flow between the atrium and 
the appendage. Furthermore, assessment of the patch itself after a period of time will 
allow appraisal of the integrity of the pericardial tissue and judgment of its ability to 
withstand the pattern of blood flow through the heart. Long-term follow up in AF patients 
who have had PPE done will allow for the evaluation of the procedure’s ability to reduce 
stroke risk, which is the goal of any surgical LAA closure. Definitive stroke risk 
reduction has not been demonstrated for any of the previously discussed forms of LAA 
closure, but this may eventually be possible. Finally, it may be useful to use resin casting 
of the LAA in order to gain an appreciation of its internal features. Knowledge of the 
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internal aspect of the appendage, such as its common branching patterns and number of 
lobes, may lend itself to the development of more effective occlusion devices.  
4.5 Conclusion 
The left atrial appendage (LAA) is of great clinical consequence for 
thrombogenesis in patients with atrial fibrillation (AF), so there is interest in its surgical 
closure. Current closure techniques are not ideal, and may even put the patient at greater 
stroke risk than before. A novel method of LAA closure, pericardial patch exclusion, 
aims to improve upon current methods and completely eliminate the appendage. Any 
operation on the LAA poses the risk of injury to the circumflex artery, which runs in 
close proximity to the base of the appendage. This investigation demonstrates that i) the 
circumflex artery is closest to the base of the LAA at the 4 and 5 o’clock positions and ii) 
that the novel pericardial patch exclusion technique is significantly more effective at 
eliminating the LAA than conventional epicardial excision. Pericardial patch exclusion of 
the LAA shows promise in completely eliminating the LAA, and may be a viable 
alternative to currently employed surgical techniques. The technique may give surgeons a 
better tool to help reduce the risk of stroke in patients with atrial fibrillation. 
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